EICHORCondition: Rheumatoid Arthritis · Sponsor: Modern Biosciences Ltd
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments. MBS2320, the drug being tested in this trial, represents a new approach to treating RA, with the potential not only to reduce levels of inflammation but to also directly prevent bone damage. The aim of this project is to test the safety, tolerability and efficacy of MBS2320 in patients with RA in combination with an existing treatment, methotrexate. Approximately 224 participants with moderate to severe active RA who have not responded to treatment with Methotrexate will be enrolled from around 45 to 55 sites around the world. Participants will be randomly assigned to receive 1 of 3 doses of MBS2320 (5 mg, 20 mg, or 40 mg) or placebo (a "dummy" drug). The maximum duration of study participation for a participant will be 22 weeks, which consists of a Screening Period of up to 4 weeks, Treatment Period of 12 weeks, and a Follow-up Period of 6 weeks. Participants on the study will be asked to attend the hospital or clinic for regular visits during which they will have planned study assessments to evaluate the effectiveness, tolerability and safety of the study drug.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Site 1201 - Univerzitetski Klinicki Centar Republike Srpske | Banja Luka, Bosnia and Herzegovina | — |
| Site 1204 - Univerzitetski Klinicki Centar Republike Srpske | Banja Luka, Bosnia and Herzegovina | — |
| Site 1202 - General Hospital Gradiška | Gradiska, Bosnia and Herzegovina | — |
| Site 1308 - Medical Center Medconsult Pleven OOD | Pleven, Bulgaria | — |
| Site 1302 - Medical Center Artmed OOD | Plovdiv, Bulgaria | — |
| Site 1303 - Diagnostic and Consulting Center Aleksandrovska EOOD | Sofia, Bulgaria | — |
| Site 1306 - Diagnostic- Consultative Center Convex EOOD | Sofia, Bulgaria | — |
| Site 1307 - Medical Center Excelsior OOD - PPDS | Sofia, Bulgaria | — |
| Site 1301 - University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD | Stara Zagora, Bulgaria | — |
| Site 1304 - Medical Center Leo Clinic EOOD, Varna | Varna, Bulgaria | — |
| Site 2103 - Enroll SpA - PPDS | Providencia, Chile | — |
| Site 2105 - CTR Estudios | Providencia, Chile | — |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05460832